Advertisement

International Journal of Clinical Pharmacy

, Volume 41, Issue 1, pp 22–29 | Cite as

Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis

  • Nashmil Ghadimi
  • Sara Kaveh
  • Hossein Shabaninejad
  • Alaadine Lijassi
  • Ali Zahed Mehr
  • Hossein HosseinifardEmail author
Review Article
  • 32 Downloads

Abstract

Background Patients with mitral valve stenosis have increased heart rate. HR reduction is known as an important treatment and therapy strategy for patients with mitral valve stenosis. Aim of the review The aim of this systematic review and meta-analysis was to compare the efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm. Methods Randomized controlled trials were searched in Cochrane Library, PubMed, Web of Science, CRD, Scopus, and Google Scholar with no start time limitation and ending June 2018. Risk of bias across was assessed by the Cochrane Risk of Bias Assessment tool. Fixed effects models were used to combine the results and the mean difference with a 95% confidence interval. This meta-analysis was performed using Meta Package in R software. Results Five studies entered meta-analysis. The total number of patients treated with ivabradine and beta-blockers was 178 and 178 respectively. The results showed that the mean of maximum HR and HR at rest was lower at about 5.03 units and upper 4.32 units respectively with use of ivabradine compared with the use of beta-blockers. These values were statistically significant. Conclusion It seems that the efficacy of ivabradine is good in comparison with betablockers, but it still requires more clinical trials.

Keywords

Heart rate Ivabradine Meta-analysis Mitral stenosis 

Notes

Acknowledgments

The authors would like to thank Dr. Masoud Mozafari for his facilitative and collaborative efforts to this research.

Funding

This work was supported by Health management and economics research center, Iran University of Medical Sciences “[Grant Number: 95-02-163-28619]”

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Supplementary material

11096_2018_778_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 13 kb)

References

  1. 1.
    De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.Google Scholar
  2. 2.
    Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.Google Scholar
  3. 3.
    Al Zaibag M, Al Kasab S, Ribeiro P, Al Fagih M. Percutaneous double-balloon mitral valvotomy for rheumatic mitral-valve stenosis. Lancet. 1986;327(8484):757–61.Google Scholar
  4. 4.
    Carabello BA. Mitral valve regurgitation. Curr Probl Cardiol. 1998;23(4):197–241.Google Scholar
  5. 5.
    Sun JP, Felner JM. Mitral Valve Stenosis. Practical Handbook of Echocardiography: 101 Case Studies. 2010:38-41.Google Scholar
  6. 6.
    Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7.Google Scholar
  7. 7.
    Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1–148.Google Scholar
  8. 8.
    Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.Google Scholar
  9. 9.
    Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.Google Scholar
  10. 10.
    Riccioni G. Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem. 2013;20(14):1817–23.Google Scholar
  11. 11.
    Alan S, Ulgen MS, Ozdemir K, Keles T, Toprak N. Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm. Angiology. 2002;53(5):575–81.Google Scholar
  12. 12.
    Monmeneu JM, Marín FO, Reyes FG, Jordán AT, García MM, Bodí VP, et al. Beta-blockade and exercise capacity in patients with mitral stenosis in sinus rhythm. J Heart Valve Dis. 2002;11(2):199–203.Google Scholar
  13. 13.
    Tardif J-C, Ponikowski P, Kahan T. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–8.Google Scholar
  14. 14.
    DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399–406.Google Scholar
  15. 15.
    De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.Google Scholar
  16. 16.
    Fala L. Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. Am Health Drug Benefits. 2016;9(Spec Feature):56.Google Scholar
  17. 17.
    Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules. 2012;17(5):4924–35.Google Scholar
  18. 18.
    Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf. 2014;6:47.Google Scholar
  19. 19.
    Werdan K, Perings S, Köster R, Kelm M, Meinertz T, Stöckl G, et al. Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies. Cardiology. 2016;135(3):141–50.Google Scholar
  20. 20.
    Agrawal V, Kumar N, Lohiya B, Sihag BK, Prajapati R, Singh T, et al. Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm. Int J Cardiol. 2016;221:562–6.Google Scholar
  21. 21.
    Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7.Google Scholar
  22. 22.
    Rajesh GN, Sajeer K, Sajeev CG, Bastian C, Vinayakumar D, Muneer K, et al. A comparative study of ivabradine and atenolol in patients with moderate mitral stenosis in sinus rhythm. Indian Heart J. 2016;68(3):311–5.Google Scholar
  23. 23.
    Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A, et al. Effect of ivabradine on heart rate and duration of exercise in patients with mild-to-moderate mitral stenosis: a randomized comparison with metoprolol. J Cardiovasc Pharmacol. 2015;65(6):552.Google Scholar
  24. 24.
    Parakh N, Chaturvedi V, Kurian S, Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail. 2012;18(4):282–8.Google Scholar
  25. 25.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.Google Scholar
  26. 26.
    Higgins J. Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence intervals. 2011.Google Scholar
  27. 27.
    Otto CM, Gaasch W, Yeon S. Clinical Manifestations and diagnosis of rheumatic mitral stenosis. UpToDate, Post, TW. 2018.Google Scholar
  28. 28.
    Mardikar H, Sahasrabhojaney V, Jalgaonkar P, Mahorkar U, Mardikar M, Waghmare B. Long term effects of atenolol in patients of mitral stenosis and normal sinus rhythm. Indian J Med Res. 1995;101:25–7.Google Scholar
  29. 29.
    Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149–55.Google Scholar
  30. 30.
    Pasceri E, Curcio A, Achille F, de Serio D, Zinzi S, Torella D. Acute reduction of transmitral gradient after I (f) channel inhibition in patients with mitral valve stenosis or a mitral annuloplasty ring [Abst 974]. Europace. 2009;11(Suppl 2):S6.Google Scholar
  31. 31.
    Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–23.Google Scholar
  32. 32.
    López-Bescós L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108(4):387–96.Google Scholar
  33. 33.
    Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36.Google Scholar
  34. 34.
    Ye L, Ke D, Chen Q, Li G, Deng W, Wu Z. Effectiveness of ivabradine in treating stable angina pectoris. Medicine. 2016;95(14):e3245.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Health Management and Economics Research CenterIran University of Medical SciencesTehranIran
  2. 2.Health Economics Group, Institute of Health & SocietyNewcastle UniversityNewcastleUK
  3. 3.Faculty of Medicine and Pharmacy of RabatMohammed V University of RabatRabatMorocco
  4. 4.Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research CenterIran University of Medical SciencesTehranIran

Personalised recommendations